Key result
Elevated Lp(a) increases CV risk in familial hypercholesterolemia despite pharmacological LDL-C lowering.
Population
Patients with familial hypercholesterolemia (FH)
Design
Review
Authors
Loading...
Lp(a) should be systematically measured in FH patients, as it contributes to residual cardiovascular risk despite LDL-C lowering.
Lp(a) should be systematically measured in FH patients, as it contributes to residual cardiovascular risk despite LDL-C lowering.
Jaafar et al. (2026) conducted a review in Familial hypercholesterolemia. Lipoprotein(a) was evaluated. Elevated Lipoprotein(a) in familial hypercholesterolemia increases cardiovascular risk that is not offset by pharmacological LDL-C lowering.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: